In a preclinical NSG mouse model, administration of CD19-CAR-T using CD4-targeted lentiviral vector (CD4-LV) displayed TH1/TH2 phenotype of the CAR-T, with a superior and faster tumor killing ability than CD8-LV CAR-T cells alone or in combination with CD4-LV. Here, CD8A is linked to neoplasm.